Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While KPV is investigated as an anti-inflammatory and barrier-protective agent in skin and mucosal models, reducing pro-inflammatory cytokines and promoting tissue repair684, Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880.
While KPV works as the C-terminal Lys-Pro-Val tripeptide fragment of α-MSH, which exerts potent anti-inflammatory effects largely via inhibition of NF-κB signaling and modulation of cytokine expression, with many actions independent of classical melanocortin receptor activation684, Liraglutide is a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880.
KPV
POMC
Liraglutide
GCG
KPV and Liraglutide are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: KPV is more often discussed in the realm of Immunology and inflammation, Gastroenterology, and Dermatology and aesthetics, whereas Liraglutide is more often associated with the realm of Metabolic and endocrine. They also influence different molecular systems, with KPV tracking more closely to Melanocortin receptor while Liraglutide centers more on GLP-1 receptor. KPV has a more natural endogenous origin, while Liraglutide is closer to synthetic analog background and their development context also differs, with KPV in Preclinical development while Liraglutide is approved. KPV takes the form of a linear peptide, whereas Liraglutide is closer to a peptide conjugate, Liraglutide incorporates palmitoylation features that are not part of KPV; while their sequence patterns also diverge, with KPV showing protein-mimetic sequence features and Liraglutide showing alpha-helical domain features.